Skip to content

Prospective Ultrafast MRI Radiomics for Breast Cancer

Ultrafast MRI Radiomics to Classify Histological Factors and Subtypes of Breast Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06104189
Enrollment
225
Registered
2023-10-27
Start date
2021-10-01
Completion date
2023-08-31
Last updated
2023-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The goal of this prospective study is to investigate the performance of ultrafast MRI radiomics in classifying histological factors and subtypes of breast cancer compared with standard MRI among radiologists with varying experience. The written informed consent was obtained from all participant. We extracted 1618 radiomic features from ultrafast and standard contrast-enhanced MRI before treatment. Classification of hormonal receptors, human epidermal growth factor receptor 2, and Ki67 status and subtypes was evaluated using the area under the receiver-operating characteristic curve (AUC) with the DeLong test.

Interventions

DIAGNOSTIC_TESTMRI

MRI based classification of breast cancer histological factors and subtypes

Sponsors

Korea University Ansan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
27 Years to 86 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with invasive breast cancer

Exclusion criteria

* Diagnosed with other cancer

Design outcomes

Primary

MeasureTime frameDescription
The signal intensity of MRI according to histological factors and subtypes of breast cancerBaseline, pre-surgeryQuantitative image values obtained from ultrafast MRI show similar performance in classifying histological factors and subtypes compared with standard MRI.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026